Dennis A. Sheeter

Dr. Dennis A. Sheeter

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
DSDennis A. Sheeter
Dennis A. Sheeter
SGSecilia Garza
Secilia Garza
HPHui Gyu Park
Hui Gyu Park
LBLorraine-Rana E. Benhamou
Lorraine-Rana E. Benhamou
NBNiharika R. Badi
Niharika R. Badi
JPJohn Powers
John Powers
MYCN amplification (MNA) and disruption of tumor suppressor microRNA (TSmiR) function are key drivers of poor outcomes in neuroblastoma (NB). While MYCN and TSmiRs regulate glucose metabolism, their role in de novo fatty acid synthesis (FAS) and unsaturated FAS (UFAS) remains poorly understood. Here, we show that FAS and UFAS (U/FAS) genes FASN, ELOVL6, SCD, FADS2, and FADS1 are upregulated in high-risk (HR) NB and that their expression is associated with lower overall survival. RNA-Seq analysis of human NB cell lines revealed parallel U/FAS gene expression patterns. Consistent with this, we found that NB-related TSmiRs were predicted to target these genes extensively. We further observed that both MYC and MYCN upregulated U/FAS pathway genes while suppressing TSmiR host gene expression, suggesting a possible U/FAS regulatory network between MYCN and TSmiRs in NB. NB cells are high in de novo synthesized omega 9 (ω9) unsaturated fatty acids and low in both ω6 and ω3, suggesting a means for NB to limit cell-autonomous immune stimulation and reactive oxygen species (ROS)-driven apoptosis from ω6 and ω3 unsaturated fatty acid derivatives, respectively. We propose a model in which MYCN and TSmiRs regulate U/FAS and play an important role in NB pathology, with implications for other MYC family-driven cancers.

21 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DSDennis A. Sheeter
Dennis A. Sheeter
SGSecilia Garza
Secilia Garza
HPHui Gyu Park
Hui Gyu Park
NBNiharika R. Badi
Niharika R. Badi
EEErika C. Espinosa
Erika C. Espinosa
JPJohn Powers
John Powers
MYCN amplification and disruption of tumor suppressor microRNA (TSmiR) function are central drivers of poor outcomes in neuroblastoma (NB). MYC, MYCN, and TSmiRs regulate glucose metabolism; however, their role in unsaturated fatty acid synthesis (UFAS) remains poorly understood. Here we show that de novo and UFAS pathway genes FASN , ELOVL6 , SCD , FADS2 , and FADS1 are upregulated in high-risk NB and are associated with poor prognosis. RNA-Seq analysis of eight human NB cell lines revealed parallel UFAS gene expression patterns. Consistent with this, we found that NB-related TSmiRs were predicted to extensively target these genes. In addition, we observed that both MYC and MYCN upregulated UFAS pathway genes while suppressing TSmiR host gene expression, thereby creating a possible UFAS regulatory network between MYCN and TSmiRs in NB. Furthermore, NB cells are high in omega 9 (ω9) unsaturated fatty acids that can be synthesized de novo and low in both ω6 and ω3, providing a plausible means for NB to limit cell-autonomous immune stimulation and reactive oxygen species (ROS)-driven apoptosis from ω6 and ω3 unsaturated fatty acid derivatives, respectively. We propose a model in which the UFAS pathway, through novel regulation by MYCN and TSmiRs, plays a key role in neuroblastoma pathology with implications for other MYC -driven cancers.

17 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
VPVishwa Patel
Vishwa Patel
MRMariya Raleigh
Mariya Raleigh
LBLorraine-Rana E. Benhamou
Lorraine-Rana E. Benhamou
XSXin Shen
Xin Shen
EEErika C. Espinosa
Erika C. Espinosa
JPJohn Powers
John Powers
The worst patient outcomes in neuroblastoma are driven by high-risk disease 1,2 , which is divided into similarly sized MYCN amplified and MYCN non-amplified patient subgroups 3 . Male patients have been reported to have slightly worse outcomes than females in all-patient analyses of multiple studies 3,4 . However, we show here that in MYCN non- amplified high-risk and stage 4s low-risk disease, female patients have significantly worse overall survival than males. Female MYCN non-amplified high-risk patients highly express H19 and DLK1 , both of which drive cell growth in vitro and are associated with worse outcomes in females but not males. Further, chromosome-specific expression analysis of these patients reveals broad sex disparities in chromosomal patterning, including female-specific retention of chromosome 11q, a pattern typically reserved for MYCN -amplified disease 5,6 . Finally, we show that H19 , a known let-7 microRNA target 7 , sequesters let-7 in females, providing a rationale for worse female survival and reconciling retention of chromosome 11q. We propose that this novel sex-based outcome disparity is driven by let-7 inhibition, expanding on a model of neuroblastoma development where let-7 mitigation is central to disease pathology 8 .